Company profile
CYTOKINETICS INC
NASDAQ:CYTKBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Aficamten | approved | — | 7 | approved |
| OMECAMTIV MECARBIL | phase2 | — | 4 | completed, terminated |
| TIRASEMTIV | phase2 | — | 3 | no active trials |
| Ulacamten | phase2 | — | 2 | active |
| SB-743921 | phase1_2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (41)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01380223 | phase1 | completed | 2005-08-01 | 2006-04-01 | Cytokinetics | A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers |
| NCT05442775 | phase3 | terminated | 2022-08-04 | 2023-06-07 | Cytokinetics | A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) |
| NCT03767855 | phase1 | completed | 2018-12-04 | 2020-01-03 | Cytokinetics | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects |
| NCT05662215 | phase1 | terminated | 2022-12-06 | 2023-08-08 | Cytokinetics | A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants |
| NCT05877053 | phase1 | completed | 2023-05-09 | 2024-11-20 | Cytokinetics | A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 219083 | NDA | CYTOKINETICS INC | ||||
Loading… | ||||||